Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.655 USD | +2.07% | +3.02% | +47.23% |
Financials (USD)
Sales 2024 * | 334M | Sales 2025 * | 390M | Capitalization | 1.51B |
---|---|---|---|---|---|
Net income 2024 * | 67M | Net income 2025 * | 114M | EV / Sales 2024 * | 4.53 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.87 x |
P/E ratio 2024 * |
22.1
x | P/E ratio 2025 * |
13
x | Employees | 624 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.47% |
Latest transcript on ADMA Biologics, Inc.
1 day | -0.91% | ||
1 week | -0.31% | ||
1 month | -1.21% | ||
3 months | +25.63% | ||
6 months | +92.90% | ||
Current year | +44.25% |
Managers | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 47 | 06-06-01 |
Compliance Officer | 37 | 10-12-31 | |
Skyler Bloom
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Guiheen
BRD | Director/Board Member | 73 | 12-07-23 |
Bryant Fong
BRD | Director/Board Member | 51 | 12-04-30 |
Steven Elms
CHM | Chairman | 60 | 06-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | +4.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 6.655 | +2.07% | 2 849 061 |
24-04-30 | 6.52 | -0.91% | 2,281,193 |
24-04-29 | 6.58 | +0.46% | 1,129,173 |
24-04-26 | 6.55 | +1.71% | 1,565,517 |
24-04-25 | 6.44 | -0.31% | 1,531,854 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.25% | 1.51B | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.98% | 31.28B | |
+57.86% | 25.27B | |
-16.24% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
-17.10% | 11.69B | |
+6.89% | 8.83B |
- Stock Market
- Equities
- ADMA Stock